You don't want a starting price that stops making sense when your dose changes. You want the real cost of compounded GLP-1 treatment over a year, with the doctor, medication and monitoring all counted. Our physician membership costs $3,588 over 12 months. Medication and any additional testing remain separate expenses.
- GoodLife Health separates physician fees from pharmacy billing, addressing cost-related problems with concierge medicine and GLP-1 care.
- Our membership costs $299 monthly or $3,588 over 12 months, excluding medication and additional testing.
- The $598 first charge covers the initial two-month commitment. It is not an extra enrollment fee.
- Compare compounded GLP-1 programs using written prescription, monitoring, renewal and cancellation terms, not an introductory quote.
- Our Biomarker Audit is included every 90 days. We prescribe branded GLP-1 medications only, never compounded versions.
An unclear bill makes an already difficult health decision harder. The fear is committing to treatment without knowing whether a dose change will alter what you owe. At GoodLife Health, we address that uncertainty with a $299 monthly physician membership that does not rise with your prescription, plus medication billed separately by the pharmacy at pharmacy cost.
The first charge is $598 for a two-month commitment, followed by $299 monthly, with cancellation available afterward. You get a defined care fee and included quarterly monitoring without tying physician revenue to medication dose. Your total treatment bill still depends on the prescription.
Why this matters
Some problems with concierge medicine are really problems of unclear scope: you know the membership fee but not which services sit outside it. The same distinction matters when comparing a compounded GLP-1 subscription with physician-led medical weight loss.
For your 2026 decision, separate the clinical relationship from the product being prescribed. A medication quote does not establish what follow-up includes and a membership quote does not establish the pharmacy bill. Neither becomes a useful annual benchmark until you know the boundaries.
The 12-month benchmark: what is fixed and what is separate
Our $3,588 annual membership benchmark covers 12 months of membership, not an all-inclusive year of GLP-1 treatment. The monthly physician fee stays at $299 across prescription choices and dose changes. The pharmacy bill is separate.
12-Month Membership Benchmark
What is fixed versus separate
| Cost dimension | Published membership terms | Annual budgeting meaning |
|---|---|---|
| Overall: 12 months of membership | $3,588 | Physician membership only. Medication is separate |
| Monthly membership rate | $299 per month | Does not change with the prescription or dose |
| Initial commitment | $598 for two months | Covers the first two months, not an added enrollment fee |
| Remaining membership payments in a full year | Ten payments of $299 | Completes the same $3,588 annual membership total |
| Included Biomarker Audit | Every 90 days. Four per year | Included within membership, not added to the annual figure |
| Medication markup | Zero markup | Pharmacy charges remain separate expenses |
| Testing beyond the included cadence | Pass-through cost | Additional testing is not included in the fixed annual figure |
The largest fixed figure is the $3,588 full-year membership. The medication markup is zero. Those figures describe different things: zero markup does not mean free medicine and a fixed membership does not mean a fixed total treatment bill.
Methodology: This 2026 benchmark annualizes our stated membership terms across 12 months and separates included services from separately billed expenses. It is a single-program cost breakdown, not a market average or a measured annual spending range for compounded GLP-1 patients.
Do not add $598 to $3,588. The initial payment is already part of the annual total. For an uninterrupted year, the first payment covers two months and the remaining ten monthly payments complete the membership expense.
The useful benchmark for another program is its equivalent written breakdown. Ask for the recurring clinical fee, the prescription charge at the dose your clinician anticipates, included monitoring and the rules governing changes. A starting quote alone cannot answer the annual-cost question.
How to use these benchmarks
- Separate the fixed fee from the variable prescription expense. Our $299 monthly membership is predictable. Your medication expense must be evaluated separately.
- Count the initial payment once. The $598 hold covers the first two months of care and sits inside the annual membership total.
- Compare included monitoring. Our four annual Biomarker Audits belong inside the $3,588 benchmark, while additional testing remains separate.
- Ask what changes when treatment changes. Our physician fee does not rise with dose escalation or a different prescription. Request the same clarity from any program you evaluate.
These checks make annual comparisons more useful without pretending that every patient receives the same prescription. You are comparing the rules governing the bill, not just the smallest number displayed beside a signup button.
Build the real annual total from separate expenses
For a 2026 budget, use this structure: annual clinical fees plus actual pharmacy charges plus separately billed testing and other care. Keep each category visible. Otherwise, a bundled quote can obscure what you are buying and what remains your responsibility.
Clinical fees
Identify what the clinical payment purchases. Ask whether it covers ongoing assessment, medication decisions, follow-up and interpretation of ordered tests or whether some of those services require separate payment.
Our Cardiometabolic Optimization Membership combines concierge-style direct primary care with the included Biomarker Audit. That is a broader clinical relationship than buying access to a prescription alone. It also means paying for ongoing care even when the medication plan does not change.
Pharmacy charges
Record the exact medication, formulation, prescribed dose and quantity associated with each pharmacy charge. Do not treat a platform's name for a program as a sufficient medication description.
We use the Unbundled Pharmacy Model: the pharmacy bills medication at pharmacy cost, with zero markup, no molecule upcharge and no dose-escalation fee from us. This removes a medication-linked charge from our business model. It does not freeze pharmacy charges or guarantee insurance coverage.
Additional testing
Distinguish the included monitoring schedule from testing ordered for a new symptom or another clinical concern. Included routine testing does not make every possible test part of a membership.
Our Biomarker Audit is included every 90 days and is drawn at Quest Diagnostics. Testing beyond that quarterly cadence is billed at pass-through cost. Ask about the purpose and financial responsibility before proceeding with additional nonurgent testing.
Other care
Keep insurance and outside medical expenses separate from a membership calculation. A direct primary care membership is not health insurance and telehealth does not replace every examination, procedure, specialist service or emergency visit.
That boundary is a limitation, not fine print to overlook. A useful plan gives you a clear clinical relationship while leaving room for the in-person and specialist care your health requires.
A fixed clinical fee is one part of the annual treatment total, not the whole bill.
Compounded versus branded GLP-1: compare the care model too
Compounded medications are not FDA-approved. FDA patient guidance on unapproved GLP-1 drugs explains that these products do not undergo the agency's premarket review for safety, effectiveness and quality. That distinction applies to the product, regardless of how polished the prescribing platform appears.
Compounding has a role for particular medical needs under applicable requirements. It does not make a compounded product an FDA-approved generic equivalent. We do not prescribe, recommend or facilitate compounded GLP-1 medications.
Compounded GLP-1 Program vs. Our Branded Care Model
| Dimension | Compounded GLP-1 program | Our branded GLP-1 care model |
|---|---|---|
| Medication status | Compounded product is not FDA-approved | Branded, FDA-approved GLP-1 medication only |
| Best for | Compounding addresses particular medical needs. Not our recommended GLP-1 pathway | Patients seeking branded treatment within ongoing metabolic and primary care |
| What needs verification | Exact formulation, dispensing pharmacy, dosing instructions, clinical rationale and applicable requirements | Exact prescribed brand, indication, pharmacy bill and individual treatment plan |
| Clinical fee | Review the program's written terms | $299 monthly, independent of prescription and dose |
| Routine monitoring | Verify what is included rather than assuming | Biomarker Audit every 90 days included |
| Main trade-off | Product does not receive FDA premarket review | Medication is separate from the membership expense |
| Our verdict | We do not offer compounded GLP-1 therapy | Choose a clinical model that separates physician payment from medication revenue |
GoodLife Health's Cardiometabolic Optimization model is best for patients who want branded GLP-1 care, quarterly biomarkers and a physician fee independent of dose. The structural advantage is specific: the prescription can change without creating a higher physician membership charge.
That advantage is not proof of the lowest total spending for every patient. A pharmacy bill, insurance decision or additional clinical need still affects the total. We make the care fee predictable without describing the entire year of healthcare as prepaid.
What you do not see in a starting quote
The most useful questions concern events that change a treatment plan. Ask them before enrollment, while you can compare written answers rather than trying to reconstruct a policy after a charge.
A dose change
Ask whether a higher prescribed dose changes the clinical fee, the pharmacy charge or both. Keep those answers separate. A clinician's decision to titrate treatment should have a medical explanation, not merely a different checkout amount.
Our membership remains $299 monthly regardless of prescription or dose. The clinical team makes treatment decisions under our protocols, while medication billing remains with the pharmacy.
The doctor costs one flat fee and the medicine carries zero markup.
A side effect
Ask who evaluates nausea, vomiting, constipation or other treatment concerns and how to obtain clinical advice. Do not assume that a refill process also provides adequate symptom assessment.
Side effects are not evidence that you should automatically increase, reduce or discontinue a medication yourself. Contact your prescribing clinician for individualized instructions. Severe or persistent abdominal pain, repeated vomiting or inability to keep fluids down warrants prompt medical evaluation rather than waiting for a subscription response.
A medication switch
Ask how a change in medication affects the care relationship and billing. A prescription decision should account for indication, medical history, response, tolerability and coverage, rather than treating every GLP-1 product as interchangeable.
For example, Zepbound and Mounjaro contain tirzepatide but have different labeled uses. Within our model, your clinician decides which medication, if any, is indicated. Your clinician determines whether treatment is appropriate.
A decision to stop
Read cancellation terms separately from medication instructions. Ending a subscription is an administrative action. Changing treatment is a clinical decision. One does not supply a safe plan for the other.
Our membership begins with a two-month commitment, followed by month-to-month billing and cancellation available afterward. Before stopping medication or moving care, ask your clinician about follow-up, monitoring and a continuity plan. Avoid turning a billing change into an unplanned treatment interruption.
The problems with concierge medicine that matter here
The label “concierge” does not tell you whether medication, laboratory work or outside care is included. It also does not establish how prescribing decisions are made. Evaluate the actual services and payment structure instead of treating the label as a clinical standard.
Paying for access without defining the work
Ask what happens between a prescription request and the next refill. You should understand who assesses your response, how symptoms are reviewed and what the ongoing care relationship includes.
Our model connects medical weight loss with metabolic, hormonal and cardiovascular health. The point of direct primary care for weight-loss management is to evaluate treatment within your broader health history, not isolate the prescription from everything else.
Paying twice without recognizing different services
Separate charges are not automatically duplicate charges. A physician membership and a pharmacy prescription purchase different services, provided each is clearly explained. The problem is an unclear boundary or an undisclosed addition.
Our separate pharmacy billing makes that boundary explicit. You pay the membership for the clinical relationship and the pharmacy for medication. Review our membership pricing with that distinction in mind, including the initial commitment and the expenses outside membership.
Mistaking a membership for complete coverage
A membership does not eliminate the need for insurance or outside care. It also cannot guarantee that a particular drug is medically appropriate, covered by insurance or free of side effects.
Our model's strength is a defined clinical fee and included monitoring, not unlimited healthcare. Keeping that limitation clear helps you choose a membership for what it actually delivers: ongoing physician-led care with an explicit medication-billing boundary.
What quarterly biomarkers add to the comparison
A medication-only annual comparison leaves out the question of what your clinician is monitoring. For 2026, our included Biomarker Audit covers Apolipoprotein B (ApoB), Lipoprotein (A), Hs-CRP, Hemoglobin A1c (HbA1c), Lipid Panel, Standard, Fasting Insulin, TSH With Reflex To Free T4 and more every 90 days.
These measurements address different parts of the same system. HbA1c reflects blood sugar exposure. ApoB informs assessment of atherogenic lipoprotein burden. Lp(a) adds inherited cardiovascular-risk information. And hs-CRP is an inflammation marker. Thyroid results require interpretation alongside symptoms and medical history.
A result outside a reference interval is not, by itself, a diagnosis and a result inside the interval does not answer every question about persistent symptoms.
A larger panel is not automatically better care. The value depends on clinical interpretation and an appropriate response.
Our Cardiometabolic Optimization approach treats weight, hormones, thyroid, blood sugar, lipids and inflammation as interconnected rather than separate purchasing decisions. That does not mean everyone needs hormone therapy or that every marker should drive a prescription. Treatment requires an individual clinical assessment.
Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. The physicians are not our employees. That attribution matters when you ask who is responsible for medical decisions.
Turn the comparison into a decision
Before committing, request a written annual-cost outline and your current medication records. Bring the exact prescription, dispensing information, recent laboratory results and concerns about tolerability or billing to the clinical assessment. Do not change dosing based on a financial comparison alone.
Use the 2026 benchmark as a test of clarity: can you identify the fixed physician fee, included monitoring, pharmacy responsibility and cancellation terms without guessing? Our answer is $299 monthly, quarterly Biomarker Audits included, medication billed separately at pharmacy cost and an initial two-month commitment.
Choose this model when you want the clinical relationship to remain financially independent of the dose. Review the membership terms and take the next step toward assessment, rather than enrolling on the assumption that a prescription is guaranteed. Medical appropriateness remains the clinician's decision.
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/